GLOW Blend

1. Studied for

   GHK-Cu: randomized human trial, topical gel on open ulcers

   A multicenter, randomized, evaluator-blinded, placebo-controlled trial tested a topical GHK-Cu gel on open ulcers, with everyone enrolled also on an aggressive standardized wound-care protocol. The published abstract reports that the gel significantly increased the percentage of closure of plantar ulcers, 98.5 percent median area percentage closure versus 60.8 percent for vehicle (p less than 0.05), and that the rate of closure was three times faster with the gel compared with standard care and vehicle. This is a single 1994 trial of a gel applied to open ulcers. It describes no other route, format or population, and it is not evidence about this blend. The population and setting are named in full in the citation title, which is reproduced verbatim. HUMAN in a randomized, evaluator-blinded, placebo-controlled human trial using a topical gel on open ulcers Preclinical strong Either convergent results from more than one independent laboratory across more than one experimental system, or a randomized controlled trial in people. The rating describes the evidence behind one finding, in the species, model and route it was measured in. It never means the finding transfers to this material's format, and it never means the combination in this vial was studied. Open for the full finding and the paper it came from.

   In the literature

   GHK-Cu: randomized human trial, topical gel on open ulcers

   A multicenter, randomized, evaluator-blinded, placebo-controlled trial tested a topical GHK-Cu gel on open ulcers, with everyone enrolled also on an aggressive standardized wound-care protocol. The published abstract reports that the gel significantly increased the percentage of closure of plantar ulcers, 98.5 percent median area percentage closure versus 60.8 percent for vehicle (p less than 0.05), and that the rate of closure was three times faster with the gel compared with standard care and vehicle. This is a single 1994 trial of a gel applied to open ulcers. It describes no other route, format or population, and it is not evidence about this blend. The population and setting are named in full in the citation title, which is reproduced verbatim.^{References 1}

   Modelin a randomized, evaluator-blinded, placebo-controlled human trial using a topical gel on open ulcers

   Confidence: strong

   Either convergent results from more than one independent laboratory across more than one experimental system, or a randomized controlled trial in people. The rating describes the evidence behind one finding, in the species, model and route it was measured in. It never means the finding transfers to this material's format, and it never means the combination in this vial was studied.

   Source

   Mulder GD, Patt LM, Sanders L, Rosenstock J, Altman MI, Hanley ME, Duncan GW. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-L-histidyl-L-lysine copper. Wound Repair and Regeneration. 1994;2(4):259-269. doi:10.1046/j.1524-475X.1994.20406.x

   Source

   How this citation was checked

   Re-resolved by the research pass on July 28, 2026. Crossref GET /works/10.1046/j.1524-475X.1994.20406.x returned this exact title, all seven authors in this order, Wound Repair and Regeneration, 1994, volume 2, issue 4, pages 259-269. doi.org resolved 302 to the Wiley record for the same DOI. The Crossref abstract contains verbatim 'A multicenter, randomized, evaluator-blinded, placebo-controlled clinical study', 'significantly increased the percentage of closure of plantar ulcers (98.5% median area percentage closure compared with 60.8% for vehicle; p < 0.05)' and 'The rate of closure was three times faster with lamin Gel treatment compared with standard care and vehicle.' The p value and the 'standard care and vehicle' wording are the source's own. This record is not indexed under the PubMed query attempted, so the DOI resolution is the load-bearing check and no PMID is claimed for it.

2. Studied for

   Thymosin beta-4: actin-sequestering biochemistry

   Thymosin beta-4 was shown to be indistinguishable from Fx, the actin-sequestering peptide that holds most of the unpolymerized actin in resting human platelets: the complete amino acid sequence of Fx was determined and found identical to thymosin beta-4. It forms a 1:1 complex with actin monomers and inhibits polymerization. The authors note that its widespread distribution and high intracellular concentration strongly suggest a significant role in regulating actin polymerization in many cell types. This is established cell biochemistry, not a tissue-repair outcome. IN VITRO biochemical work with purified peptide and purified actin (in vitro), from human platelets Preclinical strong Either convergent results from more than one independent laboratory across more than one experimental system, or a randomized controlled trial in people. The rating describes the evidence behind one finding, in the species, model and route it was measured in. It never means the finding transfers to this material's format, and it never means the combination in this vial was studied. Open for the full finding and the paper it came from.

   In the literature

   Thymosin beta-4: actin-sequestering biochemistry

   Thymosin beta-4 was shown to be indistinguishable from Fx, the actin-sequestering peptide that holds most of the unpolymerized actin in resting human platelets: the complete amino acid sequence of Fx was determined and found identical to thymosin beta-4. It forms a 1:1 complex with actin monomers and inhibits polymerization. The authors note that its widespread distribution and high intracellular concentration strongly suggest a significant role in regulating actin polymerization in many cell types. This is established cell biochemistry, not a tissue-repair outcome.^{References 2}

   Modelbiochemical work with purified peptide and purified actin (in vitro), from human platelets

   Confidence: strong

   Either convergent results from more than one independent laboratory across more than one experimental system, or a randomized controlled trial in people. The rating describes the evidence behind one finding, in the species, model and route it was measured in. It never means the finding transfers to this material's format, and it never means the combination in this vial was studied.

   Source

   Safer D, Elzinga M, Nachmias VT. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. Journal of Biological Chemistry. 1991;266(7):4029-4032. PMID 1999398

   PubMed 1999398

   How this citation was checked

   Re-resolved by the research pass on July 28, 2026. PubMed efetch on PMID 1999398 returned this exact title, the authors Safer D, Elzinga M, Nachmias VT in this order, The Journal of Biological Chemistry, 1991, volume 266, issue 7, pages 4029-32, with an abstract containing verbatim 'The complete amino acid sequence of Fx was determined and was found to be identical with that of thymosin beta 4', 'forming a 1:1 complex with actin monomers and inhibiting polymerization' and 'The widespread distribution and high intracellular concentration of thymosin beta 4 (Fx) strongly suggest that it plays a significant role in regulating actin polymerization in many cell types.' This 1991 record carries no DOI, so PubMed is the load-bearing resolution.

3. Studied for

   TB-500 and thymosin beta-4: what the literature actually contains

   A 2026 scoping review searched PubMed, Europe PMC and ClinicalTrials.gov through March 2026, screened 1,772 records and included 80 studies. Its conclusions are deflationary rather than promotional. The evidence base was weighted toward mixed and in vitro designs, and most studies evaluated thymosin beta-4 rather than TB-500, with direct TB-500 evidence limited to a single included study. The most common tissue categories were wound and skin and soft tissue, vascular and endothelial, ocular and cornea, and bone; direct musculoskeletal categories such as tendon, ligament, muscle, cartilage and spine were comparatively sparse. Human evidence was concentrated in eye and skin settings. The authors conclude that the mapped literature remains unevenly distributed and largely preclinical, with limited human evidence directly relevant to musculoskeletal applications. That sentence is the reason nothing on this page is written as a musculoskeletal claim. IN VITRO a scoping review of in vitro, animal and limited human studies Preclinical strong Either convergent results from more than one independent laboratory across more than one experimental system, or a randomized controlled trial in people. The rating describes the evidence behind one finding, in the species, model and route it was measured in. It never means the finding transfers to this material's format, and it never means the combination in this vial was studied. Open for the full finding and the paper it came from.

   In the literature

   TB-500 and thymosin beta-4: what the literature actually contains

   A 2026 scoping review searched PubMed, Europe PMC and ClinicalTrials.gov through March 2026, screened 1,772 records and included 80 studies. Its conclusions are deflationary rather than promotional. The evidence base was weighted toward mixed and in vitro designs, and most studies evaluated thymosin beta-4 rather than TB-500, with direct TB-500 evidence limited to a single included study. The most common tissue categories were wound and skin and soft tissue, vascular and endothelial, ocular and cornea, and bone; direct musculoskeletal categories such as tendon, ligament, muscle, cartilage and spine were comparatively sparse. Human evidence was concentrated in eye and skin settings. The authors conclude that the mapped literature remains unevenly distributed and largely preclinical, with limited human evidence directly relevant to musculoskeletal applications. That sentence is the reason nothing on this page is written as a musculoskeletal claim.^{References 3}

   Modela scoping review of in vitro, animal and limited human studies

   Confidence: strong

   Either convergent results from more than one independent laboratory across more than one experimental system, or a randomized controlled trial in people. The rating describes the evidence behind one finding, in the species, model and route it was measured in. It never means the finding transfers to this material's format, and it never means the combination in this vial was studied.

   Source

   McGuire F, Hughes E, Maak T, Cushman DM. Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review. Applied Sciences. 2026;16(12):6202. doi:10.3390/app16126202

   Source

   How this citation was checked

   Re-resolved by the research pass on July 28, 2026. Crossref GET /works/10.3390/app16126202 returned this exact title, the four authors Flynn McGuire, Emma Hughes, Travis Maak and Daniel M. Cushman in this order, Applied Sciences, published online 19 June 2026, volume 16, issue 12, article 6202. doi.org resolved 302 to the MDPI record at mdpi.com/2076-3417/16/12/6202. The Crossref abstract contains verbatim 'PubMed, Europe PMC, and ClinicalTrials.gov were searched through March 2026', 'Of 1772 records identified, 80 studies were included', 'most studies evaluated TB4 rather than TB-500', 'The most common tissue categories were wound/skin/soft tissue, vascular/endothelial, ocular/cornea, and bone', 'direct TB-500 evidence was limited to a single included study' and the closing sentence quoted in the description section of this page.

4. Studied for

   GHK-Cu: wound repair in animal models

   The Pickart review reports that in animal experiments GHK-Cu accelerated wound healing and increased blood vessel formation and the level of antioxidant enzymes in rabbits; that it induced systemic wound healing in rats, mice and pigs; and that it improved the healing of impaired and ischemic wounds in rats while lowering TNF-alpha and stimulating collagen synthesis. These are animal results reported secondhand inside a review; the underlying primary studies were not independently resolved here, and no human outcome is implied. in rabbit, rat, mouse and pig studies, as summarized in a peer-reviewed review Preclinical moderate A well-described result with several independent outcome measures, but from a single laboratory or a single study design. Open for the full finding and the paper it came from.

   In the literature

   GHK-Cu: wound repair in animal models

   The Pickart review reports that in animal experiments GHK-Cu accelerated wound healing and increased blood vessel formation and the level of antioxidant enzymes in rabbits; that it induced systemic wound healing in rats, mice and pigs; and that it improved the healing of impaired and ischemic wounds in rats while lowering TNF-alpha and stimulating collagen synthesis. These are animal results reported secondhand inside a review; the underlying primary studies were not independently resolved here, and no human outcome is implied.^{References 4}

   Modelin rabbit, rat, mouse and pig studies, as summarized in a peer-reviewed review

   Confidence: moderate

   A well-described result with several independent outcome measures, but from a single laboratory or a single study design.

   Source

   Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108. doi:10.1155/2015/648108

   Source

   How this citation was checked

   Re-resolved by the research pass on July 28, 2026. Crossref GET /works/10.1155/2015/648108 returned this exact title, the three authors in this order, BioMed Research International, 2015, volume 2015, article 648108; doi.org resolved 302 to the publisher record. Full text was re-fetched at PMC4508379 and returned verbatim: 'GHK-Cu accelerated wound healing and increased blood vessel formation and the level of antioxidant enzymes in rabbits. This molecule also induced systemic wound healing in rats, mice, and pigs. It improved the healing of diabetic and ischemic wounds in rats, decreasing the level of TNF-alpha and stimulating collagen synthesis.' The words 'diabetic and' are replaced in the finding above under the store's disease-name rule; the source sentence is preserved here in full so nothing is lost from the record. This review carries no PMID in the record resolved, so Crossref and PMC are the load-bearing checks.

5. Studied for

   BPC-157: surgically cut rat Achilles tendon

   In rats whose right Achilles tendon was surgically cut through, leaving a gap between the cut ends, BPC-157 given starting 30 minutes after surgery and assessed on days 1, 4, 7, 10 and 14 produced, compared with saline controls: higher load of failure, higher load of failure per area and higher Young's modulus of elasticity; significantly better Achilles functional index scores; more mononuclear cells and fewer granulocytes with better formation of fibroblasts, reticulin and collagen on microscopy; and a smaller, shallower tendon defect. In parallel cell culture, BPC-157 had no effect on cell growth on its own but reversed the growth-inhibiting effect of 4-hydroxynonenal on tendon cells. The paper's own conclusion is a case for further investigation rather than an established use. in a rat surgical model, plus cultured tendon cells Preclinical moderate A well-described result with several independent outcome measures, but from a single laboratory or a single study design. Open for the full finding and the paper it came from.

   In the literature

   BPC-157: surgically cut rat Achilles tendon

   In rats whose right Achilles tendon was surgically cut through, leaving a gap between the cut ends, BPC-157 given starting 30 minutes after surgery and assessed on days 1, 4, 7, 10 and 14 produced, compared with saline controls: higher load of failure, higher load of failure per area and higher Young's modulus of elasticity; significantly better Achilles functional index scores; more mononuclear cells and fewer granulocytes with better formation of fibroblasts, reticulin and collagen on microscopy; and a smaller, shallower tendon defect. In parallel cell culture, BPC-157 had no effect on cell growth on its own but reversed the growth-inhibiting effect of 4-hydroxynonenal on tendon cells. The paper's own conclusion is a case for further investigation rather than an established use.^{References 5}

   Modelin a rat surgical model, plus cultured tendon cells

   Confidence: moderate

   A well-described result with several independent outcome measures, but from a single laboratory or a single study design.

   Source

   Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research. 2003;21(6):976-983. doi:10.1016/S0736-0266(03)00110-4. PMID 14554208

   PubMed 14554208

   How this citation was checked

   Re-resolved by the research pass on July 28, 2026. Crossref GET /works/10.1016/S0736-0266(03)00110-4 returned this exact title, first author M. Staresinic within the full 18-author list, Journal of Orthopaedic Research, 2003, volume 21, issue 6, pages 976-983; doi.org resolved 302 to the publisher record for the same DOI. The Crossref abstract contains verbatim the transection description, 'firstly applied at 30 min after surgery', 'assessment was on day 1, 4, 7, 10 and 14', 'increased load of failure, load of failure per area and Young's modulus of elasticity', the functional-index and microscopy statements, and the 4-hydroxynonenal reversal including 'presenting with no effect on the growth of cultured cell of its own'. The animal figures printed in that abstract are deliberately not reproduced here.

6. Studied for

   BPC-157: how much of this is preclinical, and how thin the human evidence is

   A 2026 narrative review describes BPC-157 as a synthetic pentadecapeptide derived from gastric proteins that has shown reparative and anti-inflammatory properties across diverse preclinical models, with experimental evidence that it supports angiogenesis, collagen synthesis, fibroblast activity and modulation of nitric oxide pathways. The review is equally explicit about the other side: human research remains limited to small pilot studies, inconsistent preparation standards and limited clinical validation underscore the need for rigorous controlled trials, and comprehensive evaluation is required before clinical translation can be recommended. IN VITRO a review of predominantly animal and in vitro studies, with human evidence limited to small pilot studies Preclinical moderate A well-described result with several independent outcome measures, but from a single laboratory or a single study design. Open for the full finding and the paper it came from.

   In the literature

   BPC-157: how much of this is preclinical, and how thin the human evidence is

   A 2026 narrative review describes BPC-157 as a synthetic pentadecapeptide derived from gastric proteins that has shown reparative and anti-inflammatory properties across diverse preclinical models, with experimental evidence that it supports angiogenesis, collagen synthesis, fibroblast activity and modulation of nitric oxide pathways. The review is equally explicit about the other side: human research remains limited to small pilot studies, inconsistent preparation standards and limited clinical validation underscore the need for rigorous controlled trials, and comprehensive evaluation is required before clinical translation can be recommended.^{References 6}

   Modela review of predominantly animal and in vitro studies, with human evidence limited to small pilot studies

   Confidence: moderate

   A well-described result with several independent outcome measures, but from a single laboratory or a single study design.

   Source

   Yuan C, Demers A, Silva-Ortiz V, et al. From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management. International Journal of Molecular Sciences. 2026;27(6):2876. doi:10.3390/ijms27062876

   Source

   How this citation was checked

   Re-resolved by the research pass on July 28, 2026. Crossref GET /works/10.3390/ijms27062876 returned this exact title, first author Claire Yuan within the full ten-author list, International Journal of Molecular Sciences, published online 22 March 2026, volume 27, issue 6, article 2876; doi.org resolved 302 to the MDPI record at mdpi.com/1422-0067/27/6/2876. The Crossref abstract contains verbatim 'across diverse preclinical models', 'supports angiogenesis, collagen synthesis, fibroblast activity, and modulation of nitric oxide pathways', 'human research remains limited to small pilot studies' and 'inconsistent preparation standards, limited clinical validation, and regulatory restrictions underscore the need for rigorous controlled trials'. The abstract's phrase 'suggesting potential therapeutic value' is deliberately not carried over, as it is a forward-looking claim rather than an observation, and its tissue list and pain clause are dropped under the buyer-category rules recorded in the render edits.

7. Studied for

   Thymosin beta-4: mouse heart injury model

   Thymosin beta-4 promoted myocardial and endothelial cell migration in the embryonic heart and retained that property in postnatal heart muscle cells, and improved survival of embryonic and postnatal heart muscle cells in culture. The researchers found it formed a functional complex with the proteins PINCH and integrin-linked kinase, which activated the survival kinase Akt. After a coronary artery was tied off in mice, thymosin beta-4 raised integrin-linked kinase and Akt activity in the heart, improved early heart-muscle-cell survival and improved cardiac function. The authors frame the pathway as a possible new therapeutic target, not as an established use. in mice after coronary artery ligation, plus cultured heart cells Preclinical moderate A well-described result with several independent outcome measures, but from a single laboratory or a single study design. Open for the full finding and the paper it came from.

   In the literature

   Thymosin beta-4: mouse heart injury model

   Thymosin beta-4 promoted myocardial and endothelial cell migration in the embryonic heart and retained that property in postnatal heart muscle cells, and improved survival of embryonic and postnatal heart muscle cells in culture. The researchers found it formed a functional complex with the proteins PINCH and integrin-linked kinase, which activated the survival kinase Akt. After a coronary artery was tied off in mice, thymosin beta-4 raised integrin-linked kinase and Akt activity in the heart, improved early heart-muscle-cell survival and improved cardiac function. The authors frame the pathway as a possible new therapeutic target, not as an established use.^{References 7}

   Modelin mice after coronary artery ligation, plus cultured heart cells

   Confidence: moderate

   A well-described result with several independent outcome measures, but from a single laboratory or a single study design.

   Source

   Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. doi:10.1038/nature03000. PMID 15565145

   PubMed 15565145

   How this citation was checked

   Re-resolved by the research pass on July 28, 2026 on two independent paths. Crossref GET /works/10.1038/nature03000 returned this exact title, the five authors Ildiko Bock-Marquette, Ankur Saxena, Michael D. White, J. Michael DiMaio and Deepak Srivastava in this order, Nature, 2004, volume 432, issue 7016, pages 466-472; doi.org resolved 302 to nature.com/articles/nature03000. Crossref carries no abstract for this record, so PubMed efetch on PMID 15565145 was run and returned the same metadata plus an abstract containing verbatim 'thymosin beta4 formed a functional complex with PINCH and integrin-linked kinase (ILK), resulting in activation of the survival kinase Akt' and 'After coronary artery ligation in mice, thymosin beta4 treatment resulted in upregulation of ILK and Akt activity in the heart, enhanced early myocyte survival and improved cardiac function.' An earlier certification pass could not re-fetch this abstract; it is confirmed here.

8. Studied for

   Thymosin beta-4: randomized human trials, eye drops

   In a single-center, prospective, double-masked, placebo-controlled Phase II trial that randomized 72 subjects with moderate to severe dry eye for 28 days using a controlled adverse environment model, topical thymosin beta-4 eye drops failed on both primary endpoints: neither ocular discomfort nor inferior corneal staining showed a significant difference versus placebo. Several secondary endpoints did differ: discomfort scores in the controlled adverse environment on day 28 were 27 percent lower in the group given the drops (P=0.0244), and central and superior corneal staining improved significantly (P=0.0075 and P=0.0210). No adverse events were observed. A separate, much smaller multicenter Phase 2 trial in 9 participants with severe dry eye reported at day 56 a 35.1 percent reduction in ocular discomfort and a 59.1 percent reduction in total corneal fluorescein staining versus vehicle control. Both are eye-drop studies of thymosin beta-4 rather than of TB-500; the larger one missed its primary endpoints, and the smaller one is very small. Neither says anything about this blend's format or about tissue repair elsewhere in the body. HUMAN in randomized, double-masked, placebo-controlled human trials using topical eye drops Preclinical moderate A well-described result with several independent outcome measures, but from a single laboratory or a single study design. Open for the full finding and the paper it came from.

   In the literature

   Thymosin beta-4: randomized human trials, eye drops

   In a single-center, prospective, double-masked, placebo-controlled Phase II trial that randomized 72 subjects with moderate to severe dry eye for 28 days using a controlled adverse environment model, topical thymosin beta-4 eye drops failed on both primary endpoints: neither ocular discomfort nor inferior corneal staining showed a significant difference versus placebo. Several secondary endpoints did differ: discomfort scores in the controlled adverse environment on day 28 were 27 percent lower in the group given the drops (P=0.0244), and central and superior corneal staining improved significantly (P=0.0075 and P=0.0210). No adverse events were observed. A separate, much smaller multicenter Phase 2 trial in 9 participants with severe dry eye reported at day 56 a 35.1 percent reduction in ocular discomfort and a 59.1 percent reduction in total corneal fluorescein staining versus vehicle control. Both are eye-drop studies of thymosin beta-4 rather than of TB-500; the larger one missed its primary endpoints, and the smaller one is very small. Neither says anything about this blend's format or about tissue repair elsewhere in the body.^{References 8, 9}

   Modelin randomized, double-masked, placebo-controlled human trials using topical eye drops

   Confidence: moderate

   A well-described result with several independent outcome measures, but from a single laboratory or a single study design.

   Source

   Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE) model. Clinical Ophthalmology. 2015;9:877-884. doi:10.2147/OPTH.S80954. PMID 26056426. Companion: Sosne G, Dunn SP, Kim C. Thymosin beta4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34(5):491-496. doi:10.1097/ICO.0000000000000379. PMID 25826322

   PubMed 26056426 PubMed 25826322

   How this citation was checked

   Re-resolved by the research pass on July 28, 2026. PubMed efetch on PMID 26056426 returned this exact title, the authors Sosne G and Ousler GW, Clinical ophthalmology, 2015, volume 9, pages 877-84, with a structured abstract containing verbatim 'This single-center, prospective, double-masked, placebo-controlled Phase II study randomized 72 qualifying subjects', 'The primary efficacy endpoints were ocular discomfort scores and inferior corneal staining', 'Neither of the primary endpoints, ie, ocular discomfort or inferior corneal staining, showed a significant difference between treatment and control groups', 'reduced by 27% ... (P=0.0244)', 'statistically significant improvements in central and superior corneal staining ... (P=0.0075 and P=0.0210)' and 'No adverse events were observed.' PubMed efetch on PMID 25826322 returned the companion title, the authors Sosne G, Dunn SP, Kim C, Cornea, 2015, volume 34, issue 5, pages 491-6, with an abstract containing 'Nine patients with severe dry eye', '35.1% reduction of ocular discomfort' and '59.1% reduction of total corneal fluorescein staining'. doi.org resolved both DOIs 302 to Dove Press and LWW respectively. The 2 source phrases carrying banned words are preserved verbatim here as the record; the finding above is rewritten around them. The ophthalmic solution strength and the application frequency printed in both abstracts are deliberately not reproduced anywhere on this page.

9. Studied for

   GHK-Cu: extracellular-matrix and collagen turnover

   In cultured cells, GHK-Cu at very low, non-toxic concentrations stimulated both the making and the breaking down of collagen and glycosaminoglycans, and stimulated collagen, dermatan sulfate, chondroitin sulfate and the small proteoglycan decorin. The review's own words are 'both synthesis and breakdown', which means turnover, not one-directional collagen building. A separate sentence in the same review attributes modulation of matrix metalloproteinases and their inhibitors TIMP-1 and TIMP-2 to GHK, the copper-free tripeptide, not to GHK-Cu; that distinction is preserved here rather than merged. IN VITRO in cultured cells (in vitro), as summarized in a peer-reviewed review Preclinical preliminary A single study, an early mechanistic observation, or a result whose interpretation is the authors' own inference. Open for the full finding and the paper it came from.

   In the literature

   GHK-Cu: extracellular-matrix and collagen turnover

   In cultured cells, GHK-Cu at very low, non-toxic concentrations stimulated both the making and the breaking down of collagen and glycosaminoglycans, and stimulated collagen, dermatan sulfate, chondroitin sulfate and the small proteoglycan decorin. The review's own words are 'both synthesis and breakdown', which means turnover, not one-directional collagen building. A separate sentence in the same review attributes modulation of matrix metalloproteinases and their inhibitors TIMP-1 and TIMP-2 to GHK, the copper-free tripeptide, not to GHK-Cu; that distinction is preserved here rather than merged.^{References 4}

   Modelin cultured cells (in vitro), as summarized in a peer-reviewed review

   Confidence: preliminary

   A single study, an early mechanistic observation, or a result whose interpretation is the authors' own inference.

   Source

   Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108. doi:10.1155/2015/648108

   Source

   How this citation was checked

   Re-resolved by the research pass on July 28, 2026. Crossref GET /works/10.1155/2015/648108 returned this exact title, the three authors in this order, BioMed Research International, 2015, volume 2015, article 648108; doi.org resolved 302 to the publisher record. Full text re-fetched at PMC4508379 returned verbatim: 'GHK-Cu at a very low, nontoxic concentration ... stimulated both synthesis and breakdown of collagen and glycosaminoglycans', then as a separate sentence 'GHK modulated an activity of both metalloproteinases and their inhibitors (TIMP-1 and TIMP-2)', then 'GHK-Cu stimulated collagen, dermatan sulfate, chondroitin sulfate, and a small proteoglycan, decorin'. The GHK versus GHK-Cu split above reflects the source's own sentence subjects. The in vitro concentration figure printed alongside is deliberately not reproduced here.

10. Studied for

    GHK-Cu: topical cosmetic studies reported secondhand inside the review

    The Pickart review describes two different topical human studies that are often merged and should not be. First, a study that applied creams to the thigh for one month and read collagen production from skin biopsies using immunohistological techniques: increases were found in 70 percent of the women who used the GHK-Cu cream, versus 50 percent for a vitamin C cream and 40 percent for retinoic acid. The review attributes this to Abdulghani et al. 1998, whose own title calls it a pilot clinical, histologic and ultrastructural study. Second, a separate 12-week facial-cream study in 71 women, which assessed visible skin parameters and did not measure collagen. The review attributes that one to a Leyden et al. presentation at an American Academy of Dermatology meeting in February 2002, a conference proceeding rather than a peer-reviewed paper. Both are stated here strictly as reported inside the review; the review was resolved, the two primaries were not. in human topical cosmetic studies, described secondhand within a peer-reviewed review; one primary is a pilot study and the other is a conference presentation Preclinical preliminary A single study, an early mechanistic observation, or a result whose interpretation is the authors' own inference. Open for the full finding and the paper it came from.

    In the literature

    GHK-Cu: topical cosmetic studies reported secondhand inside the review

    The Pickart review describes two different topical human studies that are often merged and should not be. First, a study that applied creams to the thigh for one month and read collagen production from skin biopsies using immunohistological techniques: increases were found in 70 percent of the women who used the GHK-Cu cream, versus 50 percent for a vitamin C cream and 40 percent for retinoic acid. The review attributes this to Abdulghani et al. 1998, whose own title calls it a pilot clinical, histologic and ultrastructural study. Second, a separate 12-week facial-cream study in 71 women, which assessed visible skin parameters and did not measure collagen. The review attributes that one to a Leyden et al. presentation at an American Academy of Dermatology meeting in February 2002, a conference proceeding rather than a peer-reviewed paper. Both are stated here strictly as reported inside the review; the review was resolved, the two primaries were not.^{References 4}

    Modelin human topical cosmetic studies, described secondhand within a peer-reviewed review; one primary is a pilot study and the other is a conference presentation

    Confidence: preliminary

    A single study, an early mechanistic observation, or a result whose interpretation is the authors' own inference.

    Source

    Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108. doi:10.1155/2015/648108

    Source

    How this citation was checked

    Re-resolved by the research pass on July 28, 2026 by the same Crossref and doi.org checks. PMC4508379 full text returned verbatim 'Increases were found in 70% of the women treated with GHK-Cu, in contrast to 50% treated with the vitamin C cream, and 40% treated with retinoic acid' and, as a separate sentence, a description of the 12-week facial-cream study in 71 women. The review's reference list was read directly: reference 32 is 'Abdulghani A. A., Sherr A., Shirin S., et al. ... a pilot clinical, histologic, and ultrastructural study. Disease Management and Clinical Outcomes. 1998;1(4):136-141' and reference 33 is 'Leyden J., Stephens T., Finkey M., Appa Y., Barkovic S. Skin care benefits of copper peptide containing facial cream. Proceedings of the American Academy of Dermatology Meeting; February 2002; New York, NY, USA.' Neither primary was independently resolved. The facial-cream study's list of assessed appearance parameters is deliberately not reproduced on this page: the record states no result for any of them.

11. Studied for

    GHK: gene-expression database analysis

    Using the Broad Institute's Connectivity Map, a software gene-profiling tool, GHK was reported to significantly increase the expression of DNA-repair genes, with 47 genes stimulated and 5 genes suppressed at a threshold of at least a 50 percent increase or decrease. This is a computational database analysis, not an experiment in tissue. The same review's abstract also asserts a whole-genome regulatory effect for GHK; on a direct reading of the full text the review supplies no underlying study or methodology for that figure, so it is not reported as a result here. The review's accompanying framing of the result is the authors' own language rather than a finding, and is excluded. in a computational transcriptomic database analysis (Connectivity Map); the review specifies no cell type Preclinical preliminary A single study, an early mechanistic observation, or a result whose interpretation is the authors' own inference. Open for the full finding and the paper it came from.

    In the literature

    GHK: gene-expression database analysis

    Using the Broad Institute's Connectivity Map, a software gene-profiling tool, GHK was reported to significantly increase the expression of DNA-repair genes, with 47 genes stimulated and 5 genes suppressed at a threshold of at least a 50 percent increase or decrease. This is a computational database analysis, not an experiment in tissue. The same review's abstract also asserts a whole-genome regulatory effect for GHK; on a direct reading of the full text the review supplies no underlying study or methodology for that figure, so it is not reported as a result here. The review's accompanying framing of the result is the authors' own language rather than a finding, and is excluded.^{References 4}

    Modelin a computational transcriptomic database analysis (Connectivity Map); the review specifies no cell type

    Confidence: preliminary

    A single study, an early mechanistic observation, or a result whose interpretation is the authors' own inference.

    Source

    Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108. doi:10.1155/2015/648108

    Source

    How this citation was checked

    Re-resolved by the research pass on July 28, 2026 by the same Crossref and doi.org checks. PMC4508379 full text returned verbatim: 'Studies using the Broad Institute's Connectivity map found that GHK significantly increased the expression of DNA repair genes with 47 genes stimulated and 5 genes suppressed (more than or equal to a 50% increase or decrease)'. A full-text search for the whole-genome figure found it only in the abstract, with no supporting method or citation in the body, confirming it is an unattributed assertion. That is why it is described above rather than repeated.

12. Studied for

    GHK: antioxidant characterization

    The review characterizes GHK as able to quench some toxins, in particular those generated during lipid peroxidation, which it says makes GHK a quite efficient antioxidant, and states that GHK helps reduce the level of free ionic copper, which the authors relate to preventing oxidative damage. This is biochemical characterization of the molecule, not a demonstrated outcome in a living organism. biochemical characterization described in a peer-reviewed review; no animal or human outcome Preclinical preliminary A single study, an early mechanistic observation, or a result whose interpretation is the authors' own inference. Open for the full finding and the paper it came from.

    In the literature

    GHK: antioxidant characterization

    The review characterizes GHK as able to quench some toxins, in particular those generated during lipid peroxidation, which it says makes GHK a quite efficient antioxidant, and states that GHK helps reduce the level of free ionic copper, which the authors relate to preventing oxidative damage. This is biochemical characterization of the molecule, not a demonstrated outcome in a living organism.^{References 4}

    Modelbiochemical characterization described in a peer-reviewed review; no animal or human outcome

    Confidence: preliminary

    A single study, an early mechanistic observation, or a result whose interpretation is the authors' own inference.

    Source

    Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108. doi:10.1155/2015/648108

    Source

    How this citation was checked

    Re-resolved by the research pass on July 28, 2026 by the same Crossref and doi.org checks. PMC4508379 full text returned verbatim: 'GHK also helps to reduce the level of free ionic copper thus preventing the possibility of oxidative damage. Apart from being able to bind with copper, GHK can also quench some toxins, in particular those that are generated during lipid peroxidation. This makes GHK a quite efficient antioxidant.' The closing sentence of the finding is the page's own guard, added because the source's material is characterization rather than a measured outcome in an organism.

13. Studied for

    BPC-157: tendon cell outgrowth, survival and migration

    In rat Achilles tendon explants and isolated tendon fibroblasts grown in a dish, BPC-157 significantly accelerated the outgrowth of cells from tendon explants, significantly increased cell survival under hydrogen peroxide stress, and increased cell migration and spreading, with F-actin formation induced and the FAK and paxillin proteins more phosphorylated. The authors are explicit that cell proliferation itself was not directly affected by BPC-157 as evaluated by MTT assay, so this is a movement-and-survival result, not a cell-multiplication result. IN VITRO EX VIVO in cultured rat tendon cells and tendon explants (in vitro and ex vivo) Preclinical preliminary A single study, an early mechanistic observation, or a result whose interpretation is the authors' own inference. Open for the full finding and the paper it came from.

    In the literature

    BPC-157: tendon cell outgrowth, survival and migration

    In rat Achilles tendon explants and isolated tendon fibroblasts grown in a dish, BPC-157 significantly accelerated the outgrowth of cells from tendon explants, significantly increased cell survival under hydrogen peroxide stress, and increased cell migration and spreading, with F-actin formation induced and the FAK and paxillin proteins more phosphorylated. The authors are explicit that cell proliferation itself was not directly affected by BPC-157 as evaluated by MTT assay, so this is a movement-and-survival result, not a cell-multiplication result.^{References 10}

    Modelin cultured rat tendon cells and tendon explants (in vitro and ex vivo)

    Confidence: preliminary

    A single study, an early mechanistic observation, or a result whose interpretation is the authors' own inference.

    Source

    Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3):774-780. doi:10.1152/japplphysiol.00945.2010. PMID 21030672

    PubMed 21030672

    How this citation was checked

    Re-resolved by the research pass on July 28, 2026. Crossref GET /works/10.1152/japplphysiol.00945.2010 returned this exact title, first author Chung-Hsun Chang with co-authors Wen-Chung Tsai, Miao-Sui Lin, Ya-Hui Hsu and Jong-Hwei Su Pang, Journal of Applied Physiology, 2011, volume 110, issue 3, pages 774-780; doi.org resolved 302 to the American Physiological Society record. The Crossref abstract contains verbatim 'Cell proliferation of cultured tendon fibroblasts derived from rat Achilles tendon was not directly affected by BPC 157 as evaluated by MTT assay', the hydrogen-peroxide survival result, the transwell migration result and the FAK and paxillin phosphorylation result. The concentration-dependence qualifier printed on the migration result is dropped above under the store-wide banned word list; the migration increase itself is unchanged.

14. Studied for

    BPC-157: growth hormone receptor expression in tendon fibroblasts

    In tendon fibroblasts isolated from rat Achilles tendon and grown in a dish, a cDNA microarray flagged the growth hormone receptor as one of the most abundantly upregulated genes, and BPC-157 then increased growth hormone receptor expression, time-dependently, at both the mRNA and protein level. When growth hormone was added to cells that had been given BPC-157, proliferation increased and the downstream signaling protein Janus kinase 2 was activated. The authors propose this as a possible mechanism behind their tendon work. No magnitude figure is quoted because none was confirmed in the record resolved. IN VITRO in cultured rat tendon fibroblasts (in vitro) Preclinical preliminary A single study, an early mechanistic observation, or a result whose interpretation is the authors' own inference. Open for the full finding and the paper it came from.

    In the literature

    BPC-157: growth hormone receptor expression in tendon fibroblasts

    In tendon fibroblasts isolated from rat Achilles tendon and grown in a dish, a cDNA microarray flagged the growth hormone receptor as one of the most abundantly upregulated genes, and BPC-157 then increased growth hormone receptor expression, time-dependently, at both the mRNA and protein level. When growth hormone was added to cells that had been given BPC-157, proliferation increased and the downstream signaling protein Janus kinase 2 was activated. The authors propose this as a possible mechanism behind their tendon work. No magnitude figure is quoted because none was confirmed in the record resolved.^{References 11}

    Modelin cultured rat tendon fibroblasts (in vitro)

    Confidence: preliminary

    A single study, an early mechanistic observation, or a result whose interpretation is the authors' own inference.

    Source

    Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts. Molecules. 2014;19(11):19066-19077. doi:10.3390/molecules191119066

    Source

    How this citation was checked

    Re-resolved by the research pass on July 28, 2026. Crossref GET /works/10.3390/molecules191119066 returned this exact title, the four authors Chung-Hsun Chang, Wen-Chung Tsai, Ya-Hui Hsu and Jong-Hwei Pang in this order, Molecules, 2014, volume 19, issue 11, pages 19066-19077; doi.org resolved 302 to the MDPI record at mdpi.com/1420-3049/19/11/19066. The Crossref abstract contains verbatim 'growth hormone receptor was revealed as one of the most abundantly up-regulated genes in tendon fibroblasts by BPC 157', 'BPC 157 dose- and time-dependently increased the expression of growth hormone receptor in tendon fibroblasts at both the mRNA and protein levels' and the Janus kinase 2 activation statement. An earlier draft of this record carried a wrong journal and year (Journal of Cellular Biochemistry, 2011) and a magnitude figure that could not be confirmed; both were discarded by the research pass and neither appears here.

3 strong / 5 moderate / 6 preliminaryRated by how many independent labs and how many kinds of experiment found the same thing.